Format

Send to

Choose Destination
Obstet Gynecol. 2017 Dec;130(6):1183-1191. doi: 10.1097/AOG.0000000000002367.

Placental Alpha Microglobulin-1 Compared With Fetal Fibronectin to Predict Preterm Delivery in Symptomatic Women.

Author information

1
University of California Irvine, Orange, California; St. David's Medical Center, Austin, Texas; Summa Health, Akron, Ohio; HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona; the University of Kansas, Kansas City, Kansas; Meritus Health, Hagerstown, Maryland; South Shore Hospital, South Weymouth, Massachusetts; Promedica-The Toledo Hospital, Toledo, Ohio; St. Luke's Hospital of Kansas City, Kansas City, Missouri; the University at Buffalo-Women and Children's Hospital of Buffalo, Buffalo, New York; Stony Brook University School of Medicine, Stony Brook, New York; the University of California, Los Angeles, Los Angeles, California; the University of California San Diego, San Diego, California; the University of California, Davis, Sacramento, California; and the University of California, San Francisco, California.

Abstract

OBJECTIVE:

To compare the rapid bedside test for placental α microglobulin-1 with the instrumented fetal fibronectin test for prediction of imminent spontaneous preterm delivery among women with symptoms of preterm labor.

METHODS:

We conducted a prospective observational study on pregnant women with signs or symptoms suggestive of preterm labor between 24 and 35 weeks of gestation with intact membranes and cervical dilatation less than 3 cm. Participants were prospectively enrolled at 15 U.S. academic and community centers. Placental α microglobulin-1 samples did not require a speculum examination. Health care providers were blinded to placental α microglobulin-1 results. Fetal fibronectin samples were collected through speculum examination per manufacturer requirements and sent to a certified laboratory for testing using a cutoff of 50 ng/mL. The coprimary endpoints were positive predictive value (PPV) superiority and negative predictive value (NPV) noninferiority of placental α microglobulin-1 compared with fetal fibronectin for the prediction of spontaneous preterm birth within 7 days and within 14 days.

RESULTS:

Of 796 women included in the study cohort, 711 (89.3%) had both placental α microglobulin-1 and fetal fibronectin results and valid delivery outcomes available for analysis. The overall rate of preterm birth was 2.4% (17/711) within 7 days of testing and 4.2% (30/711) within 14 days of testing with respective rates of spontaneous preterm birth of 1.3% (9/703) and 2.9% (20/701). Fetal fibronectin was detected in 15.5% (110/711), and placental α microglobulin-1 was detected in 2.4% (17/711). The PPVs for spontaneous preterm delivery within 7 days or less among singleton gestations (n=13) for placental α microglobulin-1 and fetal fibronectin were 23.1% (3/13) and 4.3% (4/94), respectively (P<.025 for superiority). The NPVs were 99.5% (619/622) and 99.6% (539/541) for placental α microglobulin-1 and fetal fibronectin, respectively (P<.001 for noninferiority).

CONCLUSION:

Although placental α microglobulin-1 performed the same as fetal fibronectin in ruling out spontaneous preterm delivery among symptomatic women, it demonstrated statistical superiority in predicting it.

PMID:
29112664
DOI:
10.1097/AOG.0000000000002367
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center